CellResearch Therapeutics

CellResearch Therapeutics is a clinical-stage biotechnology company specializing in the development of therapeutic applications derived from umbilical cord lining stem cells. The company's proprietary platform leverages both mesenchymal and epithelial stem cells harvested from the umbilical cord lining, which offer high proliferation rates and low immunogenicity. Its lead candidate, CorLiCyte, is currently being evaluated in Phase 2 clinical trials for the treatment of chronic diabetic foot ulcers. Beyond wound healing, the company is exploring pipeline expansions into dermatology, ophthalmology, and regenerative medicine. CellResearch Therapeutics aims to provide off-the-shelf regenerative solutions that address significant unmet medical needs in chronic disease management.